Thomas G. Cotter, Thomas Beresford – 22 May 2022

Amanda P. C. S. Boteon, Andrea Schlegel, Mauricio F. Carvalho, Yuri L. Boteon – 22 May 2022

Xuezhen Zeng, Guanrui Liao, Shumin Li, Haining Liu, Xiao Zhao, Shuang Li, Kai Lei, Shenghua Zhu, Zhihang Chen, Yi Zhao, Xuxin Ren, Tianhong Su, Alfred Sze‐Lok Cheng, Sui Peng, Shuibin Lin, Ji Wang, Shuling Chen, Ming Kuang – 21 May 2022

This special interest group aims to help patients with alcohol-associated liver disease through education and research that can drive advances in patient care and government and healthcare.

The mission of the Acute on Chronic Liver Failure SIG is to promote increased understanding of the changing landscape of research into patients with chronic liver disease and cirrhosis who develop acute deterioration of their condition. Through consortia and multi-center studies, the definition, prognostication and therapeutic strategies of acute-on-chronic liver failure are explored.

The overall goal is to generate interest and encourage continuing research into this fast-increasing condition.

The mission of the Liver Cell Biology in Hepatic Diseases SIG is to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care.

The Liver Fibrosis and Cirrhosis SIG is an interactive group of investigators focusing on the pathogenesis, diagnosis and treatment of liver fibrosis and outcomes research. This SIG aims to broaden our knowledge of the disease and foster collaborations in basic and translational/clinical studies of liver fibrosis and cirrhosis with a strong focus on extracellular matrix and hepatic stellate cell biology, as well as antifibrotic treatments and trials.

The central purpose of the Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) SIG (formerly the NAFLD SIG) is to provide a forum to share ideas, foster collaboration and brainstorm together as an academy of basic and translational investigators. Our mission is to study the pathogenesis, diagnosis, natural history and development of therapeutics for metabolic dysfunction-associated steatotic Liver disease. The MASLD SIG sponsors programs at the AASLD Annual Meeting, identifies emerging topics in MASLD, and supports the educational mission of AASLD. policy.

The Public Health / Health Care Delivery SIG was formed to improve the collaboration of scientists and health care professionals from a range of disciplines who share common specialized interests.

Mission statement: To bring together AASLD members with shared interests in health services research and practice, including: disease prevention and public health, access to care, population-based disease management, improving quality of health care delivery, health economics and health policy.

The mission of the Portal Hypertension SIG is to promote collaboration and networking among investigators focused on understanding the pathophysiology, diagnosis, prevention and treatment of portal hypertension and its complications.